

Małgorzata Bobrowicz, MSc
Department of Immunology
Medical University of Warsaw
Banacha 1a, 02-097 Warsaw, Poland


Report on active participation in 19th Congress of the European Hematology Association, Milan, Italy, June 12-15, 2014

The annual Congress of the European Hematology Association held this year in Milan is the most important European conference regarding latest advances in hematology. 19th EHA congress gathered more than 9,500 participants not only from Europe but also USA, Japan or Australia. During this meeting I had a great pleasure to present the results of our research project during e-poster session *Gene therapy, immunotherapy and vaccination*. It is worth mentioning that the selection of abstract was peer-reviewed and on a base of the scientific quality abstracts were allocated as follows: 9% Oral Presentation, 47% Poster Presentation, 30% Publication Only and 14% is rejected. The e-poster session which was this year's novelty on EHA and I have to admit it was a really interesting opportunity to present my data during a short 5 minutes long presentation from an e-screen. Moreover, the conference was for me a great chance to listen to participate in many remarkable lectures and to establish future collaboration with other scientists.

Title of the poster: HDAC6 inhibition augments the efficacy of anti-CD20 monoclonal antibodies by up-regulating CD20 level in malignant B-cells

Authors: Małgorzata Bobrowicz, Michał Dwojak, Kamil Bojarczuk, Marta Siernicka, Magdalena Winiarska, Jakub Gołąb

In summary, the presented results clearly indicate that the use of HDAC6 specific small molecule inhibitors is a promising strategy of treatment for the patients suffering from non-Hodgkin lymphoma and chronic lymphocytic leukemia. We demonstrated for the first time that HDAC inhibitors regulate the expression of CD20 by interfering with its trafficking and degradation. We estimate that this therapeutic strategy can be beneficial especially in case of patients with very low CD20 level who do not fully benefit treatment based on anti-CD20 immunotherapy.





Malgorzata Bobrowicz during e-poster presentation